ClinicalTrials.gg
RecruitingNCT07154511BUTTER2Updated Nov 13, 2026

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

A Phase 1/2 interventional study of Tributyrin and Placebo in Parkinson Disease and Parkinson Disease Dementia, sponsored by Prabesh Kanel. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Prabesh Kanel · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 13, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
528th of 1,257
45 · median 36
Started
2025
with 77 others
Phase 1/2
51 of 1,650
11 open now
Primary completion
2027-05
later than 163 of 384 live
Registered
1,547th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 528th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 78 that started in 2025, is one of 51 in phase 1/2, reaches primary completion later than 163 of the 384 other live ones, and was the 1,547th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to answer are:

  1. Does tributyrin improve memory/thinking test scores and walking/balance ability?
  2. What medical problems do participants have when taking tributyrin?

Researchers will compare tributyrin to a placebo (a look-alike substance that contains no drug) to see if tributyrin works to treat Parkinson disease symptoms.

Participants will:

  1. Take tributyrin 3 times a day for 80-100 days
  2. Complete motor and cognitive testing at the clinic before and after the supplementation period
  3. Complete brain imaging (MRI scans and PET scans) before and after the supplementation period.
Read the detailed description

Changes in cognition, progressing usually to dementia, are common features of Parkinson disease (PD). These debilitating impairments respond poorly to current anti-dementia treatments and call for novel strategies. Short chain fatty acids (SFCA), in particular butyric acid (BA), are naturally present in the colon as a bacterial product of dietary fiber fermentation. There is renewed interest in SCFAs because of their potential as alternative substrates in brain metabolism, their role in the gut-brain axis, and emerging evidence that interventions promoting SCFA benefit patients with neurodegenerative disorders. Convergent evidence suggests that SFCAs may ameliorate metabolic defects secondary to mitochondrial abnormalities in PD. In addition, the gut-brain axis represents a bidirectional communication complex system involving the vagal and sympathetic nerves and humoral systems. Effects of SCFA on the brain may be indirect and/or direct. For example, fiber-induced SCFA production in the colon may result in vagal nerve-mediated changes affecting the brain. Blood and brain levels of fiber-induced SCFA are naturally very low. SCFAs can be directly administered orally, resulting in higher portal vein and systemic plasma levels that may more potently affect brain functions. Oral butyrate supplementation, however, suffers from several limitations as plasma levels are low because of rapid metabolism. In contrast, tributyrin (the triglyceride of BA) is rapidly absorbed and chemically stable in plasma, diffuses through biological membranes and is metabolized by intracellular lipases, releasing therapeutically effective BA over time directly within cells. We previously generated target engagement data showing that oral tributyrin, 500 mg three times per day (tid) po, is well tolerated and improves cognition. We also conducted the first [11C]butyrate positron emission tomography (PET) study, demonstrating that tributyrin has direct brain effects, particularly in regions relevant to cognitive functions. Significant systemic anti-inflammatory effects were also observed. A limitation of our preliminary phase 1I target engagement study is the short duration (30 days) and lack of inclusion of people with PD with more severe cognitive impairments, such as dementia. The overarching goal of this project is to perform a parallel group, double-blinded, randomized placebo-controlled phase 2 clinical trial of tributyrin, 500 mg tid po for 90 days, to validate and extend these preliminary observations in a longer duration clinical trial in people with PD with mild cognitive impairment (PD-MCI) or Parkinson disease dementia (PDD). There is critical unmet clinical need to treat people currently affected with PD who have significant cognitive impairments. Our main hypothesis is that oral tributyrin supplementation will improve cognition as well as motor functions, including cognition-dependent postural instability and gait difficulties. Successful completion of this trial would set the stage for a major, multi-center phase III clinical trial aimed at ameliorating this particularly morbid feature of PD.

03

Conditions studied

  • Parkinson Disease
  • Parkinson Disease Dementia

Browse trials for

Keywords

  • short chain fatty acid
  • butyrate
  • tributyrin
  • functional neuroimaging
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, age 45 years and over.
  • Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992) AND evidence of mild cognitive impairment (Litvan et al., 2012) OR
  • Diagnosis of DLB (McKeith et al., 2017) or PDD (Emre et al., 2007).
  • If taking cholinesterase inhibitors, benzodiazepines, memantine, or anti-psychotic medications, on a stable regimen as defined by no medication changes for these drugs in prior 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • Evidence of atypical parkinsonism.
  • to MR imaging including but not limited to pacemakers, aneurysm clips, intraocular metal, cochlear implant, or severe claustrophobia.
  • History of large vessel stroke or brain tumor
  • Regular use of typical anti-cholinergic drugs.
  • Recent history of significant, uncontrolled GI disease such as GERD, colorectal cancer.
  • Significant metabolic or uncontrolled medical comorbidity.
  • Pregnant or nursing.
  • Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.
  • Any other condition or criterion that would preclude safe and meaningful participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Tributyrin Supplementation

    Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

    Drug: Tributyrin

  • Placebo comparator
    Placebo

    Participants will take 500mg placebo for 90 days +/- 7 days.

    Drug: Placebo

Interventions

  • Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

  • DrugPlacebo

    Participants will take 500mg TID placebo for 90 days +/- 7 days.

06

What researchers measure

Primary outcomes

  1. Single composite global cognitive z-score

    A global cognitive z-score derived from a neuropsychological battery including the California Verbal Learning Test (short- and long-term memory), Delis-Kaplan Executive Function System (verbal fluency via letter fluency test, executive function via Stroop and Trail Making Test Part 4), and Benton Judgment of Line Orientation Test (visuospatial cognition). Individual test scores are normatively z-scored with age- and sex-adjustment using data from 55 cognitively normal controls (Montreal Cognitive Assessment score \> 25). All z-scores are aligned so that higher scores indicate better performance. Scores are averaged within domains and then across domains to compute the global cognitive z-score.

    Time frame: Baseline and post-intervention (83-97 days after starting supplement)

  2. Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III Score

    Movement Disorder Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS part III) is the motor examination portion of the UPDRS evaluation. Scores range from 0-132, with higher scores indicating greater severity of motor symptoms.

    Time frame: Baseline and post-intervention (83-97 days after starting supplement)

  3. Safety and tolerability of tributyrin

    Safety and tolerability are assessed by monitoring the incidence, severity, and relationship of adverse events (AEs), serious adverse events (SAEs), and discontinuations due to AEs. AE information via biweekly phone-call monitoring, and during the post-intervention study visit.

    Time frame: During and after 83-97 day supplementation period

07

Study locations

1 of 1 sites recruiting
  • Domino's Farms
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Gerianne Que, BSc · Contactqueg@med.umich.edu · 734-998-4790
    • Prabesh Kanel, PhD · Principal investigator
    • Nicolaas Bohnen, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 4, 2025
StartActual
Nov 7, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992) AND evidence of mild cognitive impairment (Litvan et al., 2012) OR Diagnosis of PDD (Emre et al., 2007).
  • AddedDiagnosis of DLB (McKeith et al., 2017) or PDD (Emre et al., 2007).
Exclusion criteria
  • EditedEvidenceHistory of large vessel stroke or mass lesion on MRI.brain tumor
Nov 13, 2026
Contact
Study contact changed: r•••@med.umich.edu · •••1168→q•••@med.umich.edu · •••4790. See the current contact
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Domino's Farms · Ann Arbor, United StatesContact r•••@med.umich.edu · •••1168→q•••@med.umich.edu · •••4790
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility 1 inclusion criterion edited, 1 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992) AND evidence of mild cognitive impairment (Litvan et al., 2012) OR Diagnosis of PDD (Emre et al., 2007).
    • AddedDiagnosis of DLB (McKeith et al., 2017) or PDD (Emre et al., 2007).
    Exclusion criteria
    • EditedEvidenceHistory of large vessel stroke or mass lesion on MRI.brain tumor
    Contact Study contact changed: r•••@med.umich.edu · •••1168→q•••@med.umich.edu · •••4790. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Domino's Farms · Ann Arbor, United StatesContact r•••@med.umich.edu · •••1168→q•••@med.umich.edu · •••4790
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07154511
Lead sponsor
Prabesh Kanel
Collaborators
Farmer Family Foundation
Responsible party
Prabesh Kanel (Research Assistant Professor of Radiology, University of Michigan) — Sponsor-investigator
First posted
Sep 4, 2025
Start date
Nov 7, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Gerianne Que, BSc
Contact
queg@med.umich.edu
734-998-4790
Prabesh Kanel, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tributyrin

Start the discussion